A Phase 1 clinical trial testing azercabtagene zapreleucel (azer-cel), TG Therapeutics’ CAR-T-cell therapy, in progressive forms of multiple sclerosis (MS) is now recruiting participants at eight sites across the U.S. The study (NCT06680037) is expected to enroll up to 32 adults with primary progressive MS or secondary progressive MS to determine whether genetically engineered immune […]
The post Trial of CAR T-cell therapy for progressive MS now recruiting in US appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com